Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
BI6727 (Volasertib)
Cat No.
CEI-0306
Description
BI 6727 potently inhibited Plk1 as well as the two closely related kinases Plk2 and Plk3 (IC 50 values 0.87, 5, and 56 nmol/L, respectively).
CAS No.
755038-65-4
Molecular Weight
618.81
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
PLK1, PLK2, PLK3
Molecular Formula
C34H50N8O3
Chemical Name
N-((1r,4r)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide
Solubility
DMSO 50 mg/mL Water
In vitro
BI 6727 potently inhibited Plk1 as well as the two closely related kinases Plk2 and Plk3 (IC 50 values 0.87, 5, and 56 nmol/L, respectively). BI 6727 inhibited proliferation of multiple cell lines derived from various cancer tissues, including carcinomas of the colon (HCT 116, EC 50 = 23 nmol/L) and lung (NCI-H460, EC 50 =21 nmol/L), melanoma (BRO, EC 50 = 11 nmol/L), and hematopoietic cancers (GRANTA-519, EC 50 = 15 nmol/L; HL-60, EC 50 =32 nmol/L; THP-1, EC 50 = 36 nmol/L and Raji, EC 50 =37 nmol/L) with EC 50 values of 11 to 37 nmol/L.
In vivo
In human carcinoma xenografts in nude mice, consecutive cycles of treatment with BI 6727 given oral or i.v. for up to 6 weeks were efficacious in multiple xenograft models. After oral administration comparing three different administration schedules (once a week, twice a week, or daily). At a total weekly dose of 50 mg/kg, all treatment schedules showed comparable efficacy and were well tolerated. In the same model, i.v. Administration of a daily dose of 15, 20, or 25 mg/kg on 2 consecutive days per week led to significant tumor growth delay and even tumor regression.
Download
Download Datasheet